Home/Filings/4/0001209191-15-029051
4//SEC Filing

AMICUS THERAPEUTICS INC 4

Accession 0001209191-15-029051

$FOLDCIK 0001178879operating

Filed

Mar 23, 8:00 PM ET

Accepted

Mar 24, 9:50 PM ET

Size

18.3 KB

Accession

0001209191-15-029051

Insider Transaction Report

Form 4
Period: 2015-03-20
Dilone Enrique
VP, Technical Operations
Transactions
  • Exercise/Conversion

    Common stock

    2015-03-20$11.51/sh+14,045$161,66964,045 total
  • Sale

    Common srock

    2015-03-20$11.51/sh14,045$161,66950,000 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2015-03-202,81242,188 total
    Exercise: $2.45From: 2015-01-03Exp: 2024-01-03Common stock (2,812 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2015-03-203,2509,750 total
    Exercise: $4.16From: 2013-11-01Exp: 2019-11-16Common Stock (3,250 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2015-03-203,46331,537 total
    Exercise: $2.52From: 2014-06-18Exp: 2023-06-18Common stock (3,463 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2015-03-201,89633,104 total
    Exercise: $4.38From: 2013-06-04Exp: 2022-06-04Common stock (1,896 underlying)
  • Exercise/Conversion

    Stock Options (right to buy)

    2015-03-202,62425,376 total
    Exercise: $3.53From: 2014-01-28Exp: 2023-01-28Common stock (2,624 underlying)
Footnotes (3)
  • [F1]The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
  • [F2]This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F3]This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.17 to $11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Issuer

AMICUS THERAPEUTICS INC

CIK 0001178879

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001178879

Filing Metadata

Form type
4
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 9:50 PM ET
Size
18.3 KB